BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 07-Nov-2017

Trading of the shares of the Company will remain suspended on record date i.e., 08.11.2017.

SQURPHARMA 05-Nov-2017

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefits from 06.11.2017 to 07.11.2017. Trading of the shares of the Company will remain suspended on record date i.e., 08.11.2017.

SQURPHARMA 24-Oct-2017

The Company has informed that the Board of Directors has approved the following matters subject to the approval of the shareholders in the General Meeting and sanction by the Hon'ble High Court Division of the Supreme Court of Bangladesh: 1. Merger of Square Formulations Ltd. with the Square Pharmaceuticals Ltd., 2. Merger of Square Herbal & Nutraceuticals Ltd. with the Square Pharmaceuticals Ltd.

SQURPHARMA 17-Oct-2017

There will be no price limit on the trading of the shares of the Company today (17.10.2017) following its corporate declaration.

SQURPHARMA 17-Oct-2017

(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 15.51, Consolidated NAV per share of Tk. 71.47 and Consolidated NOCFPS of Tk. 13.92 for the year ended on June 30, 2017 as against Tk. 13.41, Tk. 59.12 and Tk. 14.02 respectively for the same period of the previous year. (end)

SQURPHARMA 17-Oct-2017

The Board of Directors has recommended 35% cash and 7.5% stock dividend for the year ended on June 30, 2017. The Board has also approved Tk. 202.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 04.12.2017, Time: 10:00 AM, Venue: Samson H Chowdhury Centre Dhaka Club Ltd., Ramna, Dhaka. Record Date: 08.11.2017. (cont.)

SQURPHARMA 08-Oct-2017

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 16, 2017 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2017.

SQURPHARMA 20-Aug-2017

The Company has informed that a total of 2,62,47,368 shares of late Sponsor Dr. Kazi Harunar Rashid has been transmitted to his legal heirs according to the succession certificate issued by the Honorable Court: i) 1,31,23,684 shares to Mr. Kazi Iqbal Harun (son, Director of the Company), ii) 65,61,842 shares to Mrs. Nilufar Ferdous (daughter) and iii) 65,61,842 shares to Mrs. Nargis Ferdous (daughter).

SQURPHARMA 11-Jun-2017

The Company has informed that the Board of Directors has approved agreements with M/s. NAAFCO Pharma Ltd. and M/s. Sharif Pharmaceuticals Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals Limited to meet increased demand of existing products and to introduce new products.

SQURPHARMA 02-May-2017

(Q3 Un-audited): Consolidated EPS was Tk. 4.27 for January-March 2017 as against Tk. 3.64 for January-March 2016; Consolidated EPS was Tk. 11.39 for July 2016-March 2017 as against Tk. 9.74 for July'15-March'16. Consolidated NOCFPS was Tk. 12.35 for July 2016-March 2017 as against Tk. 12.08 for July 2015-March 2016. Consolidated NAV per share was Tk. 67.51 as of March 31, 2017 and Tk. 59.13 as of June 30, 2016.

Previous Next page